Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

US FDA gives green light for use of AstraZeneca's Voydeya

(Sharecast News) - America's drug regulator gave the green light to AstraZeneca's for the add-on use of Voydeya in the treatment of extravascular haemolysis (EVH) in patients with paroxysmal nocturnal haemoglobinuria (PNH). PNH is a condition under which some patients' immune systems destroy a larger proportion of red blood cells than they should, whilst EVH is the condition in which red blood cells outside of blood vessels were destroyed.

Voydeya could now be used as an add-on therapy to ravulizumab or eculizumab to treat EVH in adults with PNH.

The drug was a first-in-class, oral, Factor D inhibitor meant to address the needs of the roughly 10-20% of patients with PNH experiencing "clinically significant" EVH when they were being treated with a C5 inhibitor.

Share this article

Related Sharecast Articles

RBC Capital lifts Centrica to 'outperform', shares rally
(Sharecast News) - RBC Capital Markets upgraded Centrica on Friday to 'outperform' from 'sector perform' and lifted the price target to 170p from 145p.
Jefferies reiterates 'buy' on National Grid, trims price target
(Sharecast News) - Jefferies trimmed its price target on National Grid on Friday as it reiterated its 'buy' rating on the energy infrastructure firm.
JPMorgan reiterates 'overweight' on Whitbread
(Sharecast News) - JPMorgan Cazenove reiterated its 'overweight' rating on Whitbread on Friday as it said it continues to be one of its key convictions, and sees the recent pullback - the shares are down 20% year-to-date - as "an opportunity to revisit the story".
Short-lived sunny spell helps boost UK supermarkets
(Sharecast News) - UK supermarket sales pushed higher in May, industry data showed on Friday, boosted by a brief spell of warmer weather.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.